Form 4: Rhythm Pharmaceuticals CSO Alastair Garfield Reports RSU Vesting and Tax-Related Stock Sale

Rhythm Pharmaceuticals' Chief Scientific Officer, Alastair Garfield, reported the vesting of restricted stock units and a subsequent sale of common stock to cover tax obligations, executed under a Rule 10b5-1 plan.

Summary

• Alastair Garfield, Chief Scientific Officer of Rhythm Pharmaceuticals, Inc. (RYTM), reported transactions involving company equity.
• On July 1, 2025, 4,445 restricted stock units (RSUs) vested, resulting in the acquisition of 4,445 shares of common stock.
• On July 2, 2025, Garfield sold 1,313 shares of common stock at a price of $64.81 per share.
• Additionally, on July 2, 2025, 6 shares of common stock were sold at a price of $64.60 per share.
• These sales were conducted pursuant to a Rule 10b5-1 instruction adopted on June 25, 2024, solely for the purpose of covering withholding taxes associated with the RSU vesting.
• Following these reported transactions, Alastair Garfield directly beneficially owns 3,126 shares of common stock and 13,333 restricted stock units.
• The restricted stock units vest as to 25% of the total on each of the first four anniversaries of July 1, 2024, contingent upon the Reporting Person's continued service.

Sentiment

Score: 5

Explanation: Neutral. This is a routine Form 4 filing detailing an insider's equity compensation transactions, specifically RSU vesting and a tax-related sale, which is a common and expected event and does not typically indicate a change in company fundamentals or management's outlook.

Positives

• The stock sale was pre-planned under a Rule 10b5-1 plan, indicating a structured and compliant approach to insider transactions.
• The stated reason for the sale was to cover withholding taxes, which is a common and routine event for executives receiving equity compensation and does not typically signal a lack of confidence in the company's future.

Negatives

• An insider sale, even for tax purposes, results in a reduction of the direct ownership stake held by a key executive.

Future Outlook

NA

Industry Context

This is a routine insider transaction filing common across all industries for executives managing their equity compensation. It reflects standard practices within the biotechnology and pharmaceutical sectors for executive compensation and tax management.

Comparison to Industry Standards

• The use of a Rule 10b5-1 plan for stock sales is a standard practice among executives in publicly traded companies, including those in the pharmaceutical industry, to manage tax liabilities from equity compensation and avoid accusations of insider trading.
• Sales to cover tax withholding upon Restricted Stock Unit (RSU) vesting are a very common and expected event for executives receiving equity compensation, aligning with typical compensation structures across various industries.

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, but the reason (tax withholding) is common and generally not viewed negatively. The pre-planned nature (10b5-1) also mitigates concerns.
• Employees: No direct impact.
• Customers: No direct impact.
• Suppliers: No direct impact.
• Creditors: No direct impact.

Next Steps

• Continued vesting of Alastair Garfield's remaining 13,333 restricted stock units on the first four anniversaries of July 1, 2024, subject to continued service.

Key Dates

Keywords

Rhythm Pharmaceuticals, RYTM, Alastair Garfield, Chief Scientific Officer, Form 4, SEC filing, insider transaction, stock sale, restricted stock units, RSU vesting, Rule 10b5-1, tax withholding, beneficial ownership